Back to top
more

Assertio (ASRT)

(Real Time Quote from BATS)

$1.59 USD

1.59
1,009,738

-0.07 (-4.22%)

Updated Jul 15, 2024 01:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here is What to Know Beyond Why Assertio Holdings, Inc. (ASRT) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Assertio (ASRT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Assertio (ASRT) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Assertio (ASRT) closed the most recent trading day at $2.31, moving +1.76% from the previous trading session.

ASRT vs. STVN: Which Stock Is the Better Value Option?

by Zacks Equity Research

ASRT vs. STVN: Which Stock Is the Better Value Option?

Why Should You Retain Cigna (CI) in Your Portfolio Now?

by Zacks Equity Research

Cigna (CI) is aided by powerful segmental performances, solid demand for its Medicare plans, divestitures and solid cash-generating abilities.

Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and Humana (HUM) have performed compared to their sector so far this year.

Assertio (ASRT) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Assertio (ASRT) closed at $2.15 in the latest trading session, marking a +0.94% move from the prior day.

Is Trending Stock Assertio Holdings, Inc. (ASRT) a Buy Now?

by Zacks Equity Research

Assertio (ASRT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal

by Zacks Equity Research

Pacira's (PCRX) phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for bunionectomy meets primary and secondary endpoints.

Down 18.3% in 4 Weeks, Here's Why Assertio (ASRT) Looks Ripe for a Turnaround

by Zacks Equity Research

Assertio (ASRT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Assertio (ASRT) Flat As Market Sinks: What You Should Know

by Zacks Equity Research

Assertio (ASRT) closed at $2.24 in the latest trading session, marking no change from the prior day.

Centene (CNC) Wins Contract to Serve Texas' Foster Population

by Zacks Equity Research

Centene's (CNC) Texas subsidiary secures a contract to continue catering to the state's foster children and youth via its Medicaid plans.

ASRT vs. STVN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ASRT vs. STVN: Which Stock Is the Better Value Option?

Is Most-Watched Stock Assertio Holdings, Inc. (ASRT) Worth Betting on Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.

Assertio (ASRT) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Assertio (ASRT) closed at $2.74 in the latest trading session, marking a +1.3% move from the prior day.

Pacira (PCRX) Up on Data From Exparel Label Expansion Study

by Zacks Equity Research

Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.

Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.

Assertio (ASRT) Upgraded to Buy: Here's Why

by Zacks Equity Research

Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6%

by Zacks Equity Research

After evaluating the FDA's feedback, Erytech Pharma (ERYP) halts developing its lead candidate in leukemia. It is also looking for strategic partnerships to leverage its proprietary platform.

Tracey Ryniec headshot

5 Cheap Healthcare Stocks in 2022

by Tracey Ryniec

Energy, banks and agriculture have plenty of value stocks this year but what about healthcare?

AbbVie (ABBV), J&J's Imbruvica Gets FDA Nod for cGVHD in Kids

by Zacks Equity Research

AbbVie (ABBV) and J&J's (JNJ) Imbruvica gets FDA nod for label expansion to treat pediatric patients with chronic graft versus host disease. It is also the first BTK inhibitor approved for use in pediatric patients

BioMarin's (BMRN) Hemophilia Gene Therapy Gets Nod in EU

by Zacks Equity Research

BioMarin's (BMRN) Roctavian is the first gene therapy to get approval for hemophilia A in the European Union. The therapy has also been granted a 10-year market exclusivity.

ASRT or CORT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ASRT vs. CORT: Which Stock Is the Better Value Option?

Are Medical Stocks Lagging Axonics (AXNX) This Year?

by Zacks Equity Research

Here is how Axonics Modulation Technologies (AXNX) and Assertio (ASRT) have performed compared to their sector so far this year.

Jazz (JAZZ) Starts Study on Epidiolex for a Fourth Indication

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) initiates a two-part pivotal late-stage study evaluating its epilepsy drug, Epidiolex, in children and adolescents suffering from epilepsy with Myoclonic-Atonic Seizures (EMAS).

Assertio (ASRT) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of 100% and 11.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?